Table 1.

Summary of Trials of the GSRC from ClinicalTrials.Gov

ClinicalTrials.Gov Identifier	Study/Journal	Country/ Investigator	Sample Size	First Post/ Estimated Completion Date	Intervention	Status	Outcomes
NCT0335561260	Phase 3/ Not Applicable	China/ Han Liang	456	2017/2025	Post-operative Chemotherapy Experimental:Apatinib/XELOX Comparator: XELOX Stage: IIIA-IIIC	Not yet recruiting	1.Disease Free Survival (DFS) 2.Overall Survival (OS) 3.Adverse Events
NCT0171792459	Not Applicable/BMC Cancer	France/ Christophe Mariette	314	2012/2024	Peri-operative chemotherapy Experimental: Surgery first Comparator: Neoadjuvant chemotherapy Stage: IB, II or III	Recruiting	Percentage of dead at 2-years DFS at 2/3 years OS at 3 years R0 resection rate
NCT012498599	Not Applicable/JAMA Surgery; Annals of Surgery	France/ Christophe Mariette	2500	2010/2010	Retrospective Experimental:Signet ring cell carcinoma Comparator: non signet ring cell adenocarcinoma Stage: all stages	Completed	The median survival was significantly lower for SRC patients (21 vs 44 months, P = 0.004).
NCT0188293356	Phase 3/ BMC Cancer	France/ Olivier Glehen	367	2013/2025	Experimental: Curative gastrectomy + HIPEC+oxaliplatin Comparator: Curative gastrectomy Stage: T3 or T4	Recruiting	OS Recurrence-free survival (RFS)